SGLT2 Inhibitors Linked to Lower Epilepsy Risk - Top-Institutions - MDSpire

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

  • By

  • Kathryn Wighton

  • April 7, 2026

  • 3 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Endocrinology
    • Clinical Pharmacology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Endocrinology
    • Epidemiology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Endocrinology
    • Clinical Research

  • #4

    Taipei Medical University
    Taipei Medical University

    Taipei, Taiwan

    Key Differentiators

    • Neurology
    • Endocrinology
    • Epidemiology

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Endocrinology
    • Clinical Epidemiology

Original Source(s)

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

  • by Kathryn Wighton

  • April 7, 2026

Related Content

NIH researchers identify avenue for enhanced GLP-1-induced weight loss

  • May 22, 2026

FaReWell Depression – a randomized controlled trial of a physiotherapeutic program for the facial rehabilitation of wellbeing in depression

A systemic review of facial expression recognition (FER) in stroke: diagnosis and emerging applications in rehabilitation